CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Deucravacitinib

氘可来昔替尼 杂质对照品Deucravacitinib Impurities

40 个杂质条目40 impurity entries

本页汇总 氘可来昔替尼 的 40 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 40 impurity reference standards of Deucravacitinib. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 氘可来昔替尼(Deucravacitinib)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 分析方法Analytical MethodsFast and Sensitive Bioanalytical Method for the Determination of Deucravacitinib in Human Plasma Using HPLC-MS/MS: Application and Greenness Evaluation
    Molecules (Basel, Switzerland) · 2023 · Mahesh P et al.  ·  PMID 37513344  ·  DOI
  2. 分析方法Analytical MethodsA Validated Quantitative LC-MS/MS Method for Determination of Deucravacitinib in Rat Plasma and Its Application to a Pharmacokinetic Study
    Biomedical chromatography : BMC · 2025 · Mahesh P, Haque MA  ·  PMID 40695726  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisINDIVIDUAL ARTICLE: Evidence-Based Synthesis of Deucravacitinib: Long Term Efficacy, Safety, and Practical Use in Moderate-to-Severe Psoriasis
    Journal of drugs in dermatology : JDD · 2026 · Katz A et al.  ·  PMID 41642152
  • 合成方法SynthesisSynthesis of Radiolabeled and Stable-Isotope Labeled Deucravacitinib (BMS-986165)
    Journal of labelled compounds & radiopharmaceuticals · 2025 · Brailsford JA et al.  ·  PMID 40696716  ·  DOI

氘可来昔替尼 —— 原料药与杂质对照品Deucravacitinib — drug substance & impurities

共 41 个条目(含原料药本体)41 items incl. the drug substance
Deucravacitinib structure
原料药 APIAPI
氘可来昔替尼Deucravacitinib
Deucravacitinib
CAS No.2417137-50-7
Chemical FormulaC20H22N8O3
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 1 structure
1
氘可来昔替尼杂质1Deucravacitinib Impurity 1
Deucravacitinib Impurity 1
CAS No.22621-41-6
Chemical FormulaC8H7NO5
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 2 structure
2
氘可来昔替尼杂质2Deucravacitinib Impurity 2
Deucravacitinib Impurity 2
CAS No.90564-26-4
Chemical FormulaC9H9NO5
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 3 structure
3
氘可来昔替尼杂质3Deucravacitinib Impurity 3
Deucravacitinib Impurity 3
CAS No.722538-98-9
Chemical FormulaC8H8N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 4 structure
4
氘可来昔替尼杂质4Deucravacitinib Impurity 4
Deucravacitinib Impurity 4
CAS No.1609394-05-9
Chemical FormulaC9H8N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 5 structure
5
氘可来昔替尼杂质5Deucravacitinib Impurity 5
Deucravacitinib Impurity 5
CAS No.1609394-08-2
Chemical FormulaC10H10N4O3
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 6 structure
6
氘可来昔替尼杂质6Deucravacitinib Impurity 6
Deucravacitinib Impurity 6
CAS No.1609394-10-6
Chemical FormulaC10H12N4O
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 7 structure
7
氘可来昔替尼杂质7Deucravacitinib Impurity 7
Deucravacitinib Impurity 7
CAS No.1609394-78-6
Chemical FormulaC6H5Cl2N3O
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 8 structure
8
氘可来昔替尼杂质8Deucravacitinib Impurity 8
Deucravacitinib Impurity 8
CAS No.2417138-49-7
Chemical FormulaC16H16ClN7O2
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 9 structure
9
氘可来昔替尼杂质9Deucravacitinib Impurity 9
Deucravacitinib Impurity 9
CAS No.649729-45-3
Chemical FormulaC9H12N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 10 structure
10
氘可来昔替尼杂质10Deucravacitinib Impurity 10
Deucravacitinib Impurity 10
CAS No.1442437-21-9
Chemical FormulaC5H4N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 11 structure
11
氘可来昔替尼杂质11Deucravacitinib Impurity 11
Deucravacitinib Impurity 11
CAS No.2770470-64-7
Chemical FormulaC21H25N9O3
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 12 structure
12
氘可来昔替尼杂质12Deucravacitinib Impurity 12
Deucravacitinib Impurity 12
CAS No.1609393-79-4
Chemical FormulaC19H20N8O3
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 13 structure
13
氘可来昔替尼杂质13Deucravacitinib Impurity 13
Deucravacitinib Impurity 13
CAS No.2720564-06-5
Chemical FormulaC20H22N8O4
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 14 structure
14
氘可来昔替尼杂质14Deucravacitinib Impurity 14
Deucravacitinib Impurity 14
CAS No.2720564-22-5
Chemical FormulaC20H23N9O3
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 15 structure
15
氘可来昔替尼杂质15Deucravacitinib Impurity 15
Deucravacitinib Impurity 15
CAS No.2720564-05-4
Chemical FormulaC20H22N8O3S
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 16 structure
16
氘可来昔替尼杂质16Deucravacitinib Impurity 16
Deucravacitinib Impurity 16
CAS No.2720564-12-3
Chemical FormulaC21H24N8O4
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 17 structure
17
氘可来昔替尼杂质17Deucravacitinib Impurity 17
Deucravacitinib Impurity 17
CAS No.2771523-16-9
Chemical FormulaC19H20N8O2
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 18 structure
18
氘可来昔替尼杂质18Deucravacitinib Impurity 18
Deucravacitinib Impurity 18
CAS No.2877755-07-0
Chemical FormulaC19H20N8O3
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 19 structure
19
氘可来昔替尼杂质19Deucravacitinib Impurity 19
Deucravacitinib Impurity 19
CAS No.2754392-22-6
Chemical FormulaC16H18N8O2
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 23 structure
23
氘可来昔替尼杂质23Deucravacitinib Impurity 23
Deucravacitinib Impurity 23
CAS No.3030728-54-9
Chemical FormulaC21H24N8O3
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 24 structure
24
氘可来昔替尼杂质24Deucravacitinib Impurity 24
Deucravacitinib Impurity 24
CAS No.3030728-25-4
Chemical FormulaC21H24N8O3
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 25 structure
25
氘可来昔替尼杂质25Deucravacitinib Impurity 25
Deucravacitinib Impurity 25
CAS No.3030723-95-3
Chemical FormulaC18H19N7O2
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 27 structure
27
氘可来昔替尼杂质27Deucravacitinib Impurity 27
Deucravacitinib Impurity 27
CAS No.3030728-48-1
Chemical FormulaC25H29N9O4
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 28 structure
28
氘可来昔替尼杂质28Deucravacitinib Impurity 28
Deucravacitinib Impurity 28
CAS No.3030728-51-6
Chemical FormulaC22H22N8O4
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 29 structure
29
氘可来昔替尼杂质29Deucravacitinib Impurity 29
Deucravacitinib Impurity 29
CAS No.3030728-50-5
Chemical FormulaC24H31N9O3
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 32 structure
32
氘可来昔替尼杂质32Deucravacitinib Impurity 32
Deucravacitinib Impurity 32
CAS No.3030727-44-4
Chemical FormulaC20H22N8O2
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 33 structure
33
氘可来昔替尼杂质33Deucravacitinib Impurity 33
Deucravacitinib Impurity 33
CAS No.3026065-02-8
Chemical FormulaC9H10N4O
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 35 structure
35
氘可来昔替尼杂质35Deucravacitinib Impurity 35
Deucravacitinib Impurity 35
CAS No.2285421-41-0
Chemical FormulaC10H12N4O
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 37 structure
37
氘可来昔替尼杂质37Deucravacitinib Impurity 37
Deucravacitinib Impurity 37
CAS No.1509180-81-7
Chemical FormulaC5H3ClN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 38 structure
38
氘可来昔替尼杂质38Deucravacitinib Impurity 38
Deucravacitinib Impurity 38
CAS No.1782896-18-7
Chemical FormulaC5H3ClN2O3
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 41 structure
41
氘可来昔替尼杂质41Deucravacitinib Impurity 41
Deucravacitinib Impurity 41
CAS No.3030727-59-1
Chemical FormulaC15H13ClN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 42 structure
42
氘可来昔替尼杂质42Deucravacitinib Impurity 42
Deucravacitinib Impurity 42
CAS No.3030727-69-3
Chemical FormulaC18H17N7O4
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 44 structure
44
氘可来昔替尼杂质44Deucravacitinib Impurity 44
Deucravacitinib Impurity 44
CAS No.2245111-18-4
Chemical FormulaC19H19N7O4
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 45 structure
45
氘可来昔替尼杂质45Deucravacitinib Impurity 45
Deucravacitinib Impurity 45
CAS No.2720564-44-1
Chemical FormulaC16H15ClN6O3
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 46 structure
46
氘可来昔替尼杂质46Deucravacitinib Impurity 46
Deucravacitinib Impurity 46
CAS No.2936652-48-9
Chemical FormulaC21H23N7O4
Purity>95%询价On request
10mg25mg50mg100mg
Deucravacitinib Impurity 7-d3 structure
7-D3
氘可来昔替尼杂质7-d3Deucravacitinib Impurity 7-d3
Deucravacitinib Impurity 7-d3
CAS No.1609393-89-6
Chemical FormulaC6H2D3Cl2N3O
Purity>95%询价On request
Deucravacitinib Impurity 8-d3 structure
8-D3
氘可来昔替尼杂质8-d3Deucravacitinib Impurity 8-d3
Deucravacitinib Impurity 8-d3
CAS No.1609394-23-1
Chemical FormulaC16H13D3ClN7O2
Purity>95%询价On request
Deucravacitinib Impurity 18-d3 (BMT-153261) structure
18-D3
氘可来昔替尼杂质18-d3 (BMT-153261)Deucravacitinib Impurity 18-d3 (BMT-153261)
Deucravacitinib Impurity 18-d3 (BMT-153261)
CAS No.1609393-48-7
Chemical FormulaC19H17D3N8O3
Purity>95%询价On request
Deucravacitinib Impurity 19-d3 structure
19-D3
氘可来昔替尼杂质19-d3Deucravacitinib Impurity 19-d3
Deucravacitinib Impurity 19-d3
CAS No.2417138-48-6
Chemical FormulaC16H15D3N8O2
Purity>95%询价On request
Deucravacitinib Impurity 49-d3 structure
49-D3
氘可来昔替尼杂质49-d3Deucravacitinib Impurity 49-d3
Deucravacitinib Impurity 49-d3
CAS No.3097652-21-3
Chemical FormulaC19H17D3N8O3
Purity>95%询价On request

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

氘可来昔替尼 —— 研究文献与合成路线Deucravacitinib — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 氘可来昔替尼 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Deucravacitinib. Titles link to the original records; copyright remains with the authors and publishers.

合成路线文献Synthetic-route papers

  1. Synthesis of Radiolabeled and Stable-Isotope Labeled Deucravacitinib (BMS-986165)
    Brailsford JA, Cao K, Bonacorsi SJ · Journal of labelled compounds & radiopharmaceuticals · 2025
  2. INDIVIDUAL ARTICLE: Evidence-Based Synthesis of Deucravacitinib: Long Term Efficacy, Safety, and Practical Use in Moderate-to-Severe Psoriasis
    Katz A, Kircik C, Lamb A, et al. · Journal of drugs in dermatology : JDD · 2026

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

氘可来昔替尼 杂质谱研究要点Deucravacitinib — impurity profiling notes

下面这些是拿到 氘可来昔替尼 的 41 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 41 impurity entries for Deucravacitinib, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances